Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC, SOX, and Apatinib for Gastric Cancer Peritoneal Metastases
NCT03349827Terminated
- Sponsor
- Wuhan University
- Start
- Jan 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of Rivoceranib in gastric cancer (GC), sponsored by Wuhan University. Primary endpoint: Radical Resection Rate at 3 months. Started Jan 2018; status: terminated.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03349827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03349827.